Laurus Labs Ltd. logo

Laurus Labs Ltd. (LAURUSLABS)

Market Open
10 Aug, 10:00
XNSE XNSE
1,854. 00
+9.7
+0.5259%
544.74B Market Cap
128.39 P/E Ratio
1.6% Div Yield
1.39M Volume
0 Eps
1,844.3
Previous Close
Add Transaction
Day Range
1,832.8 1,870.8
Year Range
810.05 1,870.8
Want to track LAURUSLABS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

LAURUSLABS trading today higher at ₹1,854, an increase of 0.5259% from yesterday's close, completing a monthly increase of 21.5738% or ₹329. Over the past 12 months, LAURUSLABS stock gained 67.3285%.
LAURUSLABS pays dividends to its shareholders, with the most recent payment made on May 20, 2026. The next estimated payment will be in In 3 months on Nov 20, 2026 for a total of ₹1.2.
The last earnings report, released on Apr 22, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Laurus Labs Ltd. has completed 1 stock splits, with the recent split occurring on Sep 29, 2020.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XNSE (INR).

LAURUSLABS Chart

People also search for

Sun Pharmaceutical Industries Ltd.
1,947
+0.1337%
Tata Motors Ltd.
346.65
-0.1297%
Maruti Suzuki India Limited
14,104
+0.0497%
M&M
Mahindra & Mahindra Ltd.
3,498
-0.5402%
Bajaj Auto Limited
11,774
+0.8307%

Laurus Labs Ltd. (LAURUSLABS) FAQ

What is the stock price today?

The current price is ₹1,854.00.

On which exchange is it traded?

Laurus Labs Ltd. is listed on XNSE.

What is its stock symbol?

The ticker symbol is LAURUSLABS.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.6%.

What is its market cap?

As of today, the market cap is 544.74B.

Has Laurus Labs Ltd. ever had a stock split?

Laurus Labs Ltd. had 1 splits and the recent split was on Sep 29, 2020.

Laurus Labs Ltd. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Dr. Satyanarayana Chava M.Sc., Ph.D. CEO
XNSE Exchange
Y2090Y105 CUSIP
IN Country
6,167 Employees
8 May 2026 Last Dividend
29 Sep 2020 Last Split
- IPO Date

Overview

Laurus Labs Limited is a distinguished entity in the pharmaceutical industry, focusing on the development, manufacture, and international sale of a broad spectrum of medicines and active pharmaceutical ingredients (APIs). Originating in 2005 and headquartered in Hyderabad, India, the company has cemented its presence both domestically and globally. Its operations are not confined to medication development; they extend to providing comprehensive contract development and manufacturing services, alongside producing specialty ingredients for various health and wellness applications. This multifaceted approach ensures Laurus Labs Limited's significant contribution to healthcare and pharmaceuticals, emphasizing innovation, quality, and accessibility.

Products and Services

Laurus Labs Limited boasts a diverse portfolio of products and services designed to meet the complex needs of the healthcare and pharmaceutical industries. Here is a detailed look at their offerings:

  • Active Pharmaceutical Ingredients (APIs) and Advanced Intermediates: The company takes pride in developing and manufacturing high-quality APIs and intermediates for a range of therapeutic areas, including anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C treatments.
  • Oral Solid Formulations: Specializing in ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system treatments, Laurus Labs offers comprehensive oral solid formulation capabilities, catering to critical healthcare needs with precision and care.
  • Contract Development and Manufacturing: As a strategic partner to pharmaceutical companies worldwide, Laurus Labs provides custom development and manufacturing services, ensuring efficient, scalable, and cost-effective solutions for drug development and commercialization.
  • Specialty Ingredients: The company extends its expertise to the development and manufacturing of specialty ingredients for nutraceuticals, dietary supplements, and cosmeceuticals, prioritizing quality and innovation in wellness products.
  • Enzymatic Solutions and Recombinant Proteins: Advancing in biotechnological research, Laurus Labs is at the forefront of developing novel enzymatic solutions for industrial biotechnology applications and producing animal origin-free recombinant proteins and enzymes crucial for the biopharma industry.
  • Business Support Services: Catering to the pharmaceutical sector, Laurus Labs offers an array of business support services, leveraging their industry expertise to provide clients with strategic insights and operational excellence.

Contact Information

Address: Jubilee Hills, Hyderabad, India, 500033
Phone: 91 40 3980 4333